ALR Technologies Releases Select Results from Market Research on Diabetic Pet Industry; Market Demand High for Innovation

· GluCurve is the world’s first continuous glucose monitor (CGM) for diabetic dogs and cats
· GluCurve eliminates need for manual, costly and cumbersome “glucose curves” that are today’s standard of care
· 2017 AVMA Report shows between 28,000-32,000 veterinary practices in U.S.
· 97% of DVM survey respondents indicated they’d use a pet CGM system to diagnose and manage diabetic dogs and cats as soon as available 

SINGAPORE, Oct 22 (Bernama-GLOBE NEWSWIRE) — ALR Technologies (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, is pleased to release select results from comprehensive market research conducted by the consulting firm SmartPharma, evaluating the current approach to diabetes diagnosis, glucose monitoring and insulin treatment in cats and dogs. The conclusions speak strongly about the market demand for innovation to modernize the arcane standard of care today, which ALRT interprets as highly favorable for introducing the GluCurve™ Pet CGM (continuous glucose monitoring) as a simple, accurate, reliable and pain-free system to treat the approximately 4.5 million diabetic dogs and cats worldwide.

http://mrem.bernama.com/viewsm.php?idm=41345